AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), Arcus Biosciences ((RCUS)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca, in collaboration with Arcus Biosciences, is conducting a global Phase III study titled ‘A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy.’ The study aims to assess the efficacy and safety of combining durvalumab with domvanalimab compared to durvalumab with a placebo in treating Stage III unresectable non-small cell lung cancer (NSCLC) post-chemoradiation therapy.
The interventions being tested include durvalumab and domvanalimab, both administered as intravenous infusions. Durvalumab is an immunotherapy drug, while domvanalimab is an anti-TIGIT antibody, both intended to enhance the immune response against cancer cells.
This study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. It involves quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on February 18, 2022, with an estimated primary completion date yet to be announced. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The outcome of this study could significantly impact AstraZeneca and Arcus Biosciences’ stock performance, as successful results may enhance their competitive position in the oncology market. Investors will be keenly watching for updates, as positive data could lead to increased market confidence and stock value.
The study is currently ongoing, with further details available on the ClinicalTrials portal.